Celldex Therapeutics Presents Positive Data from
- Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment landscape -- At...
Stay updated with breaking news from Data Update. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment landscape -- At...
Item 8.01 Other Events Clinical Updates On April 23, 2023, IDEAYA Biosciences, Inc. announced interim results from its Phase 2 clinical trial evaluating darovasertib and crizotinib synthetic... | June 18, 2023
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ... | June 18, 2023
Confirmed overall response rate of 45%, disease control rate of 90% and median PFS of ~7 months in 20 evaluable First-Line MUM patientsBased on FDA meeting, initiating Phase 2/3 registrational... | April 23, 2023
Actuary Mary Pat Campbell has been giving talks ...